Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Nureca Ltd has reported financial results for the period ended June 30, 2021.
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
Drug formulations and biologics make impressive gains
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Turnover of API division of ISLL stood at Rs 856.58 crore
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Subscribe To Our Newsletter & Stay Updated